Tivic Health Systems, Inc. to Report Third Quarter 2024 Financial Results on November 14
– Conference Call and Webcast to Follow at 1:30 p.m. PST/4:30 p.m. EST – FREMONT, Calif. – November 7, 2024 – Tivic Health® Systems, Inc.
Bioelectronics is a fast-growing emerging area of medicine. The human body is an electrochemical system, in which nerves carry electrical signals. Bioelectronic devices work by modulating the electrical activity in peripheral and central nerves in order to reduce symptoms and underlying causes of disease.
Tivic Health CEO discusses the future of bioelectronic medicine at CES Digital Health Summit.
Historically, bioelectronic medicine has relied on implanted devices. Tivic Health is focused, instead, on non-invasive approaches. Non-invasive therapies can be developed with less risk and delivered more quickly to the people who need them.
Tivic and The Feinstein Institutes for Medical Research have announced a pilot study to test a novel non-invasive bioelectronic approach to vagus nerve stimulation. Tivic has also filed a provisional patent for a new approach to non-invasive vagus nerve stimulation.
Our strategic goal is to advance the field of bioelectronic medicine with a more precise approach to the treatment of cardiovascular, neurological/psychiatric, and systemic inflammatory chronic health conditions without surgery, implants, or pharmaceuticals.
Additional potential clinical applications of our technology focus on stimulation of nerves of the face and head (trigeminal, vagus, facial). These include chronic quality-of-life conditions such as temporomandibular joint disorder and tinnitus; severe, life-altering conditions such as trigeminal neuralgia; and acute conditions such as ear infections.
– Conference Call and Webcast to Follow at 1:30 p.m. PST/4:30 p.m. EST – FREMONT, Calif. – November 7, 2024 – Tivic Health® Systems, Inc.
FREMONT, Calif. – October 29, 2024– Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health tech company developing and commercializing bioelectronic medicine, announced today that the
– Presentation will highlight Tivic Health’s recent advancements in vagus nerve stimulation – SAN FRANCISCO – October 24, 2024– Tivic Health® Systems, Inc. (Nasdaq: TIVC),
SAN FRANCISCO – (Business Wire) – September 18, 2024 – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic
Partners with leading growth strategy firm, Fletcher Spaght SAN FRANCISCO – (Business Wire) – September 17, 2024 – Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a
Kimberly Bambach, Ms. Wolf’s predecessor, continues with Tivic as advisor focused on strategic transactions and special projects SAN FRANCISCO – (Business Wire) – September 13, 2024
Our first FDA-approved product, ClearUP® Sinus Pain Relief (“ClearUP”), is a patented handheld device that uses gentle pulsed electron waves to relieve symptoms of sinus and nasal inflammation such as sinus pain, sinus pressure, sinus headache, and congestion which can be caused by allergies, sinus infections, cold, and flu.
When a user glides ClearUP along the cheek, nose, and brow bone, ClearUP emits a pulsed electron wave.
This wave stimulates the nerves that pass through the sinus passages.
Vibration guides users to the optimal treatment points to relieve sinus pain and congestion.
Subjects using ClearUP reported significant improvements (compared to Sham) in sinus pain and congestion 10 minutes after use.
Subjects used ClearUP at home for 4 weeks and experienced continuous improvement with extended use.
Microcurrent technology for rapid relief of sinus pain: a randomized, placebo‐controlled, double‐blinded clinical trial.
Maul, X. A., Borchard, N. A., Hwang, P. H., & Nayak, J. V. (2019, April). In International forum of allergy & rhinology (Vol. 9, No. 4, pp. 352-356).
Read Full Paper
Prospective trial examining safety and efficacy of microcurrent stimulation for the treatment of sinus pain and congestion.
Goldsobel, A. B., Prabhakar, N., & Gurfein, B. T. (2019). Bioelectronic medicine, 5(1), 1-9.
Read Full Paper
Subinoy Das, MD CEO, US Institute for Advanced Sinus Care & Research
Alan Goldsobel, MD Board Certified Allergist and Adjunct Clinical Professor, Stanford University Medical School
Over 85 million consumers over the age of 18 experience inflammation-related symptoms related to allergies, congestion, head pain, and sinus issues. 69% of them experience
Over 85 million consumers over the age of 18 experience inflammation-related symptoms related to allergies, congestion, head pain, and sinus issues. 91% of these consumers
The Most Common Pain Points, Workarounds, and Alternative Solutions to Treat Congestion, Head Pain, and Allergies – Over 85 million consumers over the age of 18 experience inflammation-related symptoms with nasal congestion, sneezing, and headache pain the most common.
The vagus nerve is an essential nerve that connects the brain to various vital organs such as the heart, lungs, and digestive tract. Vagus nerve stimulation (VNS) through electrical impulses has been found to have therapeutic benefits for a range of medical conditions.
The information included on this site reflects Tivic Health research and development pipeline and is not intended for promotional purposes. There are significant risks and uncertainties in medical device research and development.
Clinical and regulatory hurdles may cause pipeline devices to be discontinued or delayed, or to fail to reach the market. There can be no guarantee that pipeline devices will receive regulatory clearances or that they will prove to be commercially successful. Tivic Health assumes no duty to update this information.
Stay in the know with all things Tivic.